Development and Implementation of Electronic Health Record–Integrated Model‐Informed Clinical Decision Support Tools for the Precision Dosing of Drugs

Imagine it is 2030, and the drug label is in the cloud, is interactive, and can provide model‐informed precision dosing support based on an individual's genomic and physiologic makeup that is uploaded via a user‐friendly interface. Precision medicine has vastly improved our ability to provide tailored therapeutics, and groundbreaking advances in noninvasive systems have generated smart wearable devices that can follow our physiologic state and drug exposure in real time. One device consists of a microfluidic drug biosensor with a transmitter attached to the skin and a mobile app that displays concentration values and trends while issuing alerts and providing suggestions on dose changes when out of range. This sounds compelling, but why has model‐informed precision dosing not yet become common clinical reality in 2020?

[1]  D. Mould,et al.  Clinical Decision Support Tools: The Evolution of a Revolution , 2016, Clinical pharmacology and therapeutics.

[2]  M. Dubinsky,et al.  Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD Patients , 2016, The AAPS Journal.

[3]  Dermot Diamond,et al.  Glucose Sensing for Diabetes Monitoring: Recent Developments , 2017, Sensors.

[4]  Roger W. Jelliffe,et al.  Are Vancomycin Trough Concentrations Adequate for Optimal Dosing? , 2013, Antimicrobial Agents and Chemotherapy.

[5]  D. Mould,et al.  Prediction of Individual Serum Infliximab Concentrations in Inflammatory Bowel Disease by a Bayesian Dashboard System , 2018, Journal of clinical pharmacology.

[6]  Peter Timmins,et al.  From ‘fixed dose combinations’ to ‘a dynamic dose combiner’: 3D printed bi‐layer antihypertensive tablets , 2018, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[7]  Michael N Neely,et al.  Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. , 2014, The Lancet. Infectious diseases.

[8]  L Tian,et al.  Wearable sensors: modalities, challenges, and prospects. , 2018, Lab on a chip.

[9]  T. Buclin,et al.  Benchmarking Therapeutic Drug Monitoring Software: A Review of Available Computer Tools , 2012, Clinical Pharmacokinetics.

[10]  J. S. Leeder,et al.  Design and Testing of an EHR-Integrated, Busulfan Pharmacokinetic Decision Support Tool for the Point-of-Care Clinician , 2016, Front. Pharmacol..

[11]  Nicholas E. Manicke,et al.  Analysis of biofluids by paper spray MS: advances and challenges. , 2016, Bioanalysis.

[12]  R. Peck,et al.  The right dose for every patient: a key step for precision medicine , 2015, Nature Reviews Drug Discovery.

[13]  J. Masson,et al.  Biosensors and nanobiosensors for therapeutic drug and response monitoring. , 2016, The Analyst.

[14]  Eric Chang,et al.  Review and Validation of Bayesian Dose‐Optimizing Software and Equations for Calculation of the Vancomycin Area Under the Curve in Critically Ill Patients , 2018, Pharmacotherapy.

[15]  M. Wiese,et al.  Infliximab Maintenance Dosing in Inflammatory Bowel Disease: an Example for In Silico Assessment of Adaptive Dosing Strategies , 2017, The AAPS Journal.

[16]  Y. Daali,et al.  Why Has Model‐Informed Precision Dosing Not Yet Become Common Clinical Reality? Lessons From the Past and a Roadmap for the Future , 2017, Clinical pharmacology and therapeutics.

[17]  A. Schumitzky,et al.  Prospective Trial on the Use of Trough Concentration versus Area under the Curve To Determine Therapeutic Vancomycin Dosing , 2017, Antimicrobial Agents and Chemotherapy.

[18]  G. Tomlinson,et al.  Hydroxyurea for Children with Sickle Cell Anemia in Sub‐Saharan Africa , 2019, The New England journal of medicine.

[19]  B. Canaud,et al.  An international observational study suggests that artificial intelligence for clinical decision support optimizes anemia management in hemodialysis patients. , 2016, Kidney international.

[20]  R. Jelliffe,et al.  Practical, Individualized Dosing: 21st Century Therapeutics and the Clinical Pharmacometrician , 2010, Journal of clinical pharmacology.

[21]  H. T. Soh,et al.  Closed-loop control of circulating drug levels in live animals , 2017, Nature Biomedical Engineering.

[22]  M. Narayan,et al.  Evaluating Performance of a Decision Support System to Improve Methotrexate Pharmacotherapy in Children and Young Adults With Cancer , 2011, Therapeutic drug monitoring.

[23]  P. Rutgeerts,et al.  Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. , 2014, Gastroenterology.

[24]  M. Alexander,et al.  3D printing of five-in-one dose combination polypill with defined immediate and sustained release profiles. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[25]  R. Ware,et al.  Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia , 2019, American journal of hematology.

[26]  Kevin R. Dufendach,et al.  Electronic Health Record–Embedded Decision Support Platform for Morphine Precision Dosing in Neonates , 2020, Clinical pharmacology and therapeutics.

[27]  A. Vinks.  From Molecule to Patient and Ways to Get the Dose Precisely Right , 2019, Clinical pharmacology and therapeutics.

[28]  A. Vinks,et al.  Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. , 1999, Therapeutic drug monitoring.

[29]  J. Barrett.  Paediatric models in motion: requirements for model‐based decision support at the bedside , 2015, British journal of clinical pharmacology.

[30]  R. Peck.  Precision Medicine Is Not Just Genomics: The Right Dose for Every Patient. , 2018, Annual review of pharmacology and toxicology.

[31]  F. Collins,et al.  A new initiative on precision medicine. , 2015, The New England journal of medicine.

[32]  D. Mould.  Why therapeutic drug monitoring is needed for monoclonal antibodies and how do we implement this? , 2016, Clinical pharmacology and therapeutics.

[33]  V. Jiménez‐Yuste,et al.  Experience of tailoring prophylaxis using factor VIII pharmacokinetic parameters estimated with myPKFiT® in patients with severe haemophilia A without inhibitors , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

[34]  T. Wiltshire,et al.  Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact , 2017, Clinical and translational science.

[35]  A. Vinks,et al.  Precision Medicine—Nobody Is Average , 2017, Clinical pharmacology and therapeutics.

[36]  D. Mould,et al.  DOP56 Dashboard driven vs. conventional dosing of infliximab in inflammatory bowel disease patients: the PRECISION trial , 2019, Journal of Crohn's and Colitis.

[37]  Federico Polo,et al.  Biosensing Technologies for Therapeutic Drug Monitoring. , 2017, Current medicinal chemistry.

[38]  J. Wetzels,et al.  Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome , 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[39]  Huyuan Yang,et al.  Exposure–efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn’s Disease , 2017, Journal of Crohn's & colitis.

[40]  L B Sheiner,et al.  Forecasting individual pharmacokinetics , 1979, Clinical pharmacology and therapeutics.

[41]  The Emperor's New Clothes: Prospective Observational Evaluation of the Association between Initial Vancomycin Exposure and Failure Rates among Adult Hospitalized Patients with MRSA Bloodstream Infections (PROVIDE). , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.